Assertion Not publicly verifiable AI assessment confidence: 75% certainty 4/5 debate potential 1/5

InnoPlexus raises around $10M in total venture capital

Gunjan Bhardwaj · 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue · Feb 24, 2018 · at 5:55

Gunjan Bhardwaj, founder and CEO of InnoPlexus, discusses the company's fundraising history on Nathan Latka's podcast.

0:00 / 0:09exact quote · 9.3s

720p mp4 · rendered on demand · StarZero watermark

“It was till now including pre-series A, we have raised around ten million dollars.”

quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →

The claim, plainly

InnoPlexus has raised around $10 million in total funding, including its pre-Series A.

a quote alone can be ambiguous, so this restates it with the references and context of the conversation around it resolved. AI-written; the tape below the player is the source.

Assessment

Gunjan Bhardwaj stated in February 2018 that Innoplexus had raised around $10 million in cumulative funding, encompassing its pre-Series A and subsequent equity financing. Contemporary reporting confirms that Innoplexus closed a $3 million pre-Series A round from HCS Beteiligungsgesellschaft in December 2016, followed by a Series A round in 2017 led by Apeiron Investment Group. However, the specific financial terms and dollar valuation of the 2017 Series A round were not publicly disclosed in press releases or public regulatory filings. Because private round amounts for this period remain undisclosed in available public venture records, the precise cumulative funding figure cannot be independently verified or falsified.

December 2016 reporting confirms Innoplexus completed a $3 million pre-Series A round with HCS Beteiligungsgesellschaft.
2017 investment records confirm Christian Angermayer / Apeiron Investment Group led Innoplexus's Series A round, but the specific round total was undisclosed.
Public venture databases and SEC filings from ATAI Life Sciences document the equity sequence but lack a public standalone dollar breakdown for the Series A round prior to February 2018.

Checked against

[1] techstory.in [2] yourstory.com [3] everybodywiki.com [4] psychedelicinvest.com [5] hexgn.com [6] atai.com [7] sec.gov [8] partex.ai

"Innoplexus" funding "HCS" OR "ATAI" 2016 OR 2017 OR 2018 "Apeiron Investment Group" "Innoplexus" "Series A" Innoplexus Gunjan Bhardwaj funding HCS Beteiligungsgesellschaft "Innoplexus" raised "pre-Series A" OR "Series A" Innoplexus funding round Series A pre Series A Innoplexus funding million Crunchbase Pitchbook

assessed as of 2026-09-02

This assessment is an AI reading of a public statement, made against the cited references with the confidence shown. It can be wrong. The quote, the tape and the references are all on this page; if something is off, use report an error below. full disclaimer →

Mentioned

Gunjan Bhardwaj InnoPlexus

⚑ Spot an error? Report it

More from Gunjan Bhardwaj

Assertion Not checkable as stated

InnoPlexus reports zero customer churn for its licensed software products

“We haven't lost a single client that has licensed our products.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 12:59 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Assertion Not checkable as stated

InnoPlexus replaces Indian and Chinese manual data curation monopolies with AI

“That has been a monopoly of large data service companies manually curating data, hiring thousands of analysts in India and China. We are replacing all of that using AI leveraged algorithms.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 3:00 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Disclosure

InnoPlexus charges six figures annually for a ten-user SaaS deployment

“Well, as I mentioned it depends on the number of users for something like 10 users or so, it could the price could go range of six digit dollar figures. Depending on what indication and what therapeutic area they are looking at.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 3:56 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Assertion Not checkable as stated

InnoPlexus generates 85% of revenue from recurring SaaS

“85%.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 6:36 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Disclosure

Bhardwaj: InnoPlexus serves around six major pharmaceutical clients

“So we have around six big pharma clients for various therapeutic areas.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 7:08 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

Assertion Not checkable as stated

InnoPlexus operates at a revenue run rate slightly over €3.5M

“In terms of run rate, we would be slightly above half of that.”

Gunjan Bhardwaj Feb 24, 2018 ▶ 11:48 945 He's Democratizing Health Data Across Big Pharma With 200 Customers, $3.5m Revenue

InnoPlexus raises around $10M in total venture capital

More from Gunjan Bhardwaj

Turn any episode into a week of clips.